Clopidogrel HCl | CAS# 120202-65-5 (HCl) | inhibitor of ADP-induced platelet aggregation

MedKoo Cat#: 413153 | Name: Clopidogrel HCl

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Clopidogrel HCl is the salt form of Clopidogrel (free base), an inhibitor of ADP-induced platelet aggregation acting by direct inhibition of adenosine diphosphate (ADP) binding to its receptor and of the subsequent ADP-mediated activation of the glycoprotein GPIIb/IIIa complex.

Chemical Structure

Clopidogrel HCl

CAS#120202-65-5 (HCl)

Theoretical Analysis

MedKoo Cat#: 413153

Name: Clopidogrel HCl

CAS#: 120202-65-5 (HCl)

Chemical Formula: C16H17Cl2NO2S

Exact Mass: 357.0357

Molecular Weight: 358.28

Elemental Analysis: C, 53.64; H, 4.78; Cl, 19.79; N, 3.91; O, 8.93; S, 8.95

Price and Availability

Size	Price	Availability	Quantity

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

120202-66-6 (sulfate) 120202-65-5 (HCl) 90055-48-4 (racemic) 744256-69-7 (besylate) 120202-67-7 (HBr)

Synonym

Clopidogrel HCl; UNII-426O7XWS6Y

IUPAC/Chemical Name

methyl (S)-2-(2-chlorophenyl)-2-(6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl)acetate hydrochloride

InChi Key

XIHVAFJSGWDBGA-RSAXXLAASA-N

InChi Code

InChI=1S/C16H16ClNO2S.ClH/c1-20-16(19)15(12-4-2-3-5-13(12)17)18-8-6-14-11(10-18)7-9-21-14;/h2-5,7,9,15H,6,8,10H2,1H3;1H/t15-;/m0./s1

SMILES Code

COC([C@H](c1c(Cl)cccc1)N2CCc3c(C2)ccs3)=O.Cl

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 358.28 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1. Clopidogrel Pharmacogenetics. Pereira NL, Rihal CS, So DYF, Rosenberg Y, Lennon RJ, Mathew V, Goodman SG, Weinshilboum RM, Wang L, Baudhuin LM, Lerman A, Hasan A, Iturriaga E, Fu YP, Geller N, Bailey K, Farkouh ME. 2. The Role of Clopidogrel in 2020: A Reappraisal. Patti G, Micieli G, Cimminiello C, Bolognese L. Cardiovasc Ther. 2020 Mar 16;2020:8703627. doi: 10.1155/2020/8703627. eCollection 2020. 3. Interactions between clopidogrel and traditional Chinese medicine. Hu Y, Wang J. J Thromb Thrombolysis. 2019 Oct;48(3):491-499. doi: 10.1007/s11239-019-01945-3. PMID: 31471773 Review. 4. Anticoagulation with or without Clopidogrel after Transcatheter Aortic-Valve Implantation. Nijenhuis VJ, Brouwer J, Delewi R, Hermanides RS, Holvoet W, Dubois CLF, Frambach P, De Bruyne B, van Houwelingen GK, Van Der Heyden JAS, Toušek P, van der Kley F, Buysschaert I, Schotborgh CE, Ferdinande B, van der Harst P, Roosen J, Peper J, Thielen FWF, Veenstra L, Chan Pin Yin DRPP, Swaans MJ, Rensing BJWM, van 't Hof AWJ, Timmers L, Kelder JC, Stella PR, Baan J, Ten Berg JM. N Engl J Med. 2020 Apr 30;382(18):1696-1707. doi: 10.1056/NEJMoa1915152. Epub 2020 Mar 29. 5. Clopidogrel versus ticagrelor or prasugrel in patients aged 70 years or older with non-ST-elevation acute coronary syndrome (POPular AGE): the randomised, open-label, non-inferiority trial. Gimbel M, Qaderdan K, Willemsen L, Hermanides R, Bergmeijer T, de Vrey E, Heestermans T, Tjon Joe Gin M, Waalewijn R, Hofma S, den Hartog F, Jukema W, von Birgelen C, Voskuil M, Kelder J, Deneer V, Ten Berg J. 6. Aspirin with or without Clopidogrel after Transcatheter Aortic-Valve Implantation. Brouwer J, Nijenhuis VJ, Delewi R, Hermanides RS, Holvoet W, Dubois CLF, Frambach P, De Bruyne B, van Houwelingen GK, Van Der Heyden JAS, Toušek P, van der Kley F, Buysschaert I, Schotborgh CE, Ferdinande B, van der Harst P, Roosen J, Peper J, Thielen FWF, Veenstra L, Chan Pin Yin DRPP, Swaans MJ, Rensing BJWM, van 't Hof AWJ, Timmers L, Kelder JC, Stella PR, Baan J, Ten Berg JM. N Engl J Med. 2020 Oct 8;383(15):1447-1457. doi: 10.1056/NEJMoa2017815. Epub 7. Compared efficacy of clopidogrel and ticagrelor in treating acute coronary syndrome: a meta-analysis. Wang D, Yang XH, Zhang JD, Li RB, Jia M, Cui XR. BMC Cardiovasc Disord. 2018 Nov 29;18(1):217. doi: 10.1186/s12872-018-0948-4. PMID: 30497387 Free PMC article. Review. 8. Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCI: The STOPDAPT-2 Randomized Clinical Trial. Watanabe H, Domei T, Morimoto T, Natsuaki M, Shiomi H, Toyota T, Ohya M, Suwa S, Takagi K, Nanasato M, Hata Y, Yagi M, Suematsu N, Yokomatsu T, Takamisawa I, Doi M, Noda T, Okayama H, Seino Y, Tada T, Sakamoto H, Hibi K, Abe M, Kawai K, Nakao K, Ando K, Tanabe K, Ikari Y, Hanaoka KI, Morino Y, Kozuma K, Kadota K, Furukawa Y, Nakagawa Y, Kimura T; STOPDAPT-2 Investigators. JAMA. 2019 Jun 25;321(24):2414-2427. doi: 10.1001/jama.2019.8145. 9. Clopidogrel Pharmacogenetics - Why the Wait? Roden DM. N Engl J Med. 2019 Oct 24;381(17):1677-1678. doi: 10.1056/NEJMe1911496. 10. Benefits and Risks of Clopidogrel vs. Aspirin Monotherapy after Recent Ischemic Stroke: A Systematic Review and Meta-Analysis. Paciaroni M, Ince B, Hu B, Jeng JS, Kutluk K, Liu L, Lou M, Parfenov V, Wong KSL, Zamani B, Paek D, Min Han J, Del Aguila M, Girotra S.